Related coverage linked through entity extraction aliases.
Feb 17, 2026
Two financial services firms raised their price targets for Moderna in mid-February 2026, with RBC Capital increasing its target to $30 and Evercore ISI Group raising its target to $35, both maintaining neutral ratings.
Feb 14, 2026
Moderna challenges FDA's refusal to review its mRNA flu vaccine application, citing shifting regulatory expectations. The company reported Q4 revenue of $678 million as COVID vaccine uptake fell 26% in 2025.
Feb 13, 2026
Moderna reported Q4 2025 revenue of $700 million and full-year revenue of $1.9 billion, beating estimates while cutting operating expenses by $2.2 billion. The FDA refused to file the company's seasonal flu vaccine application.
